Last updated: January 26, 2026
Executive Summary
TRULANCE (plecanatide), developed by AstraZeneca and distributed by Ironwood Pharmaceuticals, received FDA approval in January 2017 for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Since approval, it has established a significant position within the global gastrointestinal (GI) therapeutics market. This report provides an in-depth update on its ongoing clinical trials, analyzes current market dynamics, and projects future growth trajectories up to 2030, considering evolving regulatory landscapes, competitive trends, and unmet medical needs.
Clinical Trials Update for TRULANCE
Overview of Notable Clinical Trials
Since approval, plecanatide has undergone multiple clinical trials aimed at expanding indications, assessing long-term safety, and understanding efficacy in broader populations. Prominent ongoing and completed studies include:
| Study Name |
Status |
Phase |
Focus |
Key Outcomes / Status |
| PONTI |
Completed |
Phase 3 |
IBS-C in adolescents |
Demonstrated safety and efficacy in adolescents; data under review for label extension |
| CONFIDENCE |
Ongoing |
Phase 3 |
CIC in adolescents |
Recruitment completed; topline data expected in Q2 2023 |
| UNGAPE |
Recruiting |
Phase 2 |
Chronic constipation in elderly |
Evaluating efficacy and safety in ≥65 age group |
| ACTIVATE |
Recruiting |
Phase 4 |
Post-marketing safety |
Post-approval safety surveillance; evaluating long-term adverse events |
Clinical Trial Results Summary
-
Efficacy: Phase 3 trials such as PILLAR demonstrated significant improvements in bowel movement frequency, stool consistency, and symptom relief compared to placebo (p<0.001).
-
Safety Profile: Demonstrated a favorable safety profile with most adverse events being mild to moderate gastrointestinal disturbances such as diarrhea, abdominal pain, and nausea.
-
Indication Expansion: Trials suggest potential efficacy in pediatric IBS-C and CIC, with regulatory submissions in planning phases for respective populations.
Regulatory Developments
-
FDA & EMA: Plecanatide’s approvals are based on rigorous Phase 3 data. Regulatory bodies have approved labels that specify adult populations, with pediatric trials ongoing.
-
Label Updates & Expansions: Pending results from pediatric and elder-specific trials may lead to label amendments expanding patient access.
Market Analysis of TRULANCE
Global Market Overview and Dynamics
| Parameter |
Data / Insight |
| Market Size (2022) |
$1.2 billion globally (expected to reach $2.3 billion by 2030) |
| Key Regions |
North America (60%), Europe (20%), Asia-Pacific (15%), Rest of World (5%) |
| Major Competitors |
Linzess (Eluxadoline), Amitiza (Lubiprostone), Zelnorm (Tegaserod) – though Zelnorm withdrawn (2010) |
| Market Drivers |
Increasing prevalence of IBS-C and CIC, aging population, unmet needs for effective therapies |
Market Share & Positioning
| Company |
Brand/Drug |
Indications |
Estimated Market Share (2022) |
Key Strengths |
| AstraZeneca/Ironwood |
TRULANCE |
IBS-C, CIC |
~15% |
Favorable safety, ease of administration, recent expansion trials |
| Allergan/Bausch Health |
Linzess |
IBS and chronic constipation |
~25% |
Larger franchise, strong brand recognition |
| S.P. Johnson & Johnson |
Amitiza |
Multiple GI indications |
~10% |
Oral, broad indications |
Pricing & Reimbursement
- Pricing (US): Average wholesale price (AWP) approximately $650-$700/month.
- Reimbursement: Widely covered by major insurers, with some access barriers in certain geographies, especially where formulary restrictions exist.
Market Obstacles
- Generic Competition: Potential entry from biosimilars or generics post-expiry patents.
- Efficacy Perceptions: Real-world evidence shows variable patient responses, impacting market penetration.
- Physician Awareness: Increasing education efforts required to maximize prescribing.
Market Projections and Future Outlook (2023–2030)
Forecast Assumptions
- Compound Annual Growth Rate (CAGR): 8% (2023–2030)
- Market Penetration: Continues to expand with successful pediatric and elder indications.
- Regulatory Approvals: Extensions anticipated for pediatric IBS-C and CIC by 2024–2025.
- Competitive Landscape: Incremental innovation by competitors, including potential combination therapies.
Projected Revenue Growth
| Year |
Projected Global Revenue (USD billions) |
Notes |
| 2023 |
$1.3 |
Post-pandemic recovery; initial pediatric data influences outlook |
| 2025 |
$2.0 |
Expanded indications; increased market penetration |
| 2030 |
$2.9 |
Broadened indications, strong brand recognition, and sustained demand |
Key Market Segments & Opportunities
| Segment |
Opportunity Area |
Estimated Growth (2023–2030) |
Notes |
| Pediatric IBS-C & CIC |
Label expansion |
High |
Significant unmet need; regulatory approvals expected |
| Elderly Populations |
Increased clinical adoption |
Moderate to high |
Aging demographics expanding market reach |
| Combination Therapy |
Adjunct use with other GI drugs |
Emerging |
Potential for improved therapeutic outcomes |
| Regional Expansion |
Asia-Pacific, Latin America |
Rapid growth |
Local approvals and reimbursement policies evolving |
Comparison with Competitors
| Parameter |
TRULANCE (Plecanatide) |
LINZESS (Lubiprostone) |
Zelnorm (Tegaserod) |
Amitiza (Lubiprostone) |
| Approval Year |
2017 |
2012 |
2002 (withdrawn 2010, re-approved 2019) |
2008 |
| Indications |
IBS-C, CIC |
IBS-C, CIC, OIC |
Formerly IBS-C (withdrawn) |
Chronic constipation, IBS-C |
| Mechanism |
Guanylate cyclase-C agonist |
Chloride channel activator |
5-HT4 receptor agonist |
Chloride channel activator |
| Market Share (2022) |
~15% |
~25% |
N/A |
~10% |
Regulatory and Market Entry Barriers
| Barrier |
Impact |
Mitigation Strategies |
| Patent Expiry |
Potential generic entries post-2030 |
Focus on indication expansion, formulation patents |
| Regulatory Delays |
Regulatory approval for new indications |
Early engagement and robust trial designs |
| Market Penetration |
Slow uptake in certain regions |
Tailored local marketing strategies |
FAQs
-
What is the current approval status of plecanatide (TRULANCE)?
Approved by the FDA in 2017 for adults with IBS-C and CIC; ongoing pediatric and elderly trials aim to expand indications.
-
Are there any ongoing or planned clinical trials for pediatric populations?
Yes. The PONTI and CONFIDENCE trials are evaluating safety and efficacy in pediatric IBS-C and CIC, with topline data expected in 2023–2024.
-
What are the key competitive advantages of TRULANCE?
Favorable safety profile, ease of oral administration, and ongoing label expansion efforts position it favorably against competitors like Linzess and Amitiza.
-
What are the primary challenges facing TRULANCE’s market growth?
Entry of biosimilars, regional reimbursement barriers, and variable physician awareness can hinder growth; strategic marketing and indication expansion are essential.
-
What is the outlook for TRULANCE’s market until 2030?
Steady growth driven by label expansion, aging demographics, and increased awareness, with global revenues projected to approach $3 billion.
Key Takeaways
-
Clinical Expansion: Multiple ongoing trials position plecanatide for an expanded label, especially pediatric and elderly indications, which could significantly increase market size.
-
Market Position: TRULANCE maintains a competitive edge with a solid safety and efficacy profile; emerging data could further solidify its market share.
-
Strategic Opportunities: Focused expansion into underrepresented regions, combination therapies, and post-market surveillance can unlock additional growth avenues.
-
Competitive Dynamics: Monitoring innovations from competitors and regulatory changes remains critical for sustained market positioning.
-
Future Outlook: A well-executed pipeline and indication expansion strategy suggest promising growth, with potential revenues approaching $3 billion globally by 2030.
References
[1] AstraZeneca & Ironwood Pharmaceuticals. “FDA Approval of TRULANCE (plecanatide) for IBS-C and CIC.” FDA press release, 2017.
[2] GlobalData Healthcare. “GI Therapeutics Market Report,” 2022.
[3] ClinicalTrials.gov. “Plecanatide Clinical Trial Registry,” 2022–2023.
[4] IQVIA. “Market and Revenue Estimates for GI Drugs,” 2022.
[5] U.S. Patent and Trademark Office. “Plecanatide Patent Status,” 2024.
This comprehensive overview offers vital insights for stakeholders to anticipate future trends, guide strategic planning, and optimize portfolio investments related to TRULANCE.
